Collplant Biotechnologies Stock Today
| CLGN Stock | USD 4.25 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 16
|
Collplant Biotechnologies is selling at 4.25 as of the 28th of November 2024; that is No Change since the beginning of the trading day. The stock's open price was 4.2485. Collplant Biotechnologies has less than a 16 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Collplant Biotechnologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of January 2018 | Category Healthcare | Classification Health Care |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. The company has 11.45 M outstanding shares of which 15.43 K shares are currently shorted by private and institutional investors with about 1.38 trading days to cover. More on Collplant Biotechnologies
Moving together with Collplant Stock
| 0.82 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Collplant Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Collplant Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Yehiel Tal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCollplant Biotechnologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Collplant Biotechnologies' financial leverage. It provides some insight into what part of Collplant Biotechnologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collplant Biotechnologies (CLGN) is traded on NASDAQ Exchange in USA. It is located in Weizmann Science Park, Rehovot, Israel, 7670104 and employs 75 people. Collplant Biotechnologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.85 M. Collplant Biotechnologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 11.45 M outstanding shares of which 15.43 K shares are currently shorted by private and institutional investors with about 1.38 trading days to cover.
Collplant Biotechnologies currently holds about 36.29 M in cash with (2.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.27.
Check Collplant Biotechnologies Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Collplant Biotechnologies is $48.85 Million. Collplant Biotechnologies shows 10.1 percent of its outstanding shares held by insiders and 12.23 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Collplant Ownership Details
Collplant Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Parallel Advisors, Llc | 2024-06-30 | 3.3 K |
Collplant Biotechnologies Historical Income Statement
Collplant Stock Against Markets
Collplant Biotechnologies Corporate Management
| Oren Fahimipoor | Vice Operations | Profile | |
| Michal Roytman | VP Marketing | Profile | |
| Pr Shoseyov | Founder Scientist | Profile | |
| Eran CPA | Deputy CFO | Profile | |
| Elana Gazal | Vice Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.